Olivier Jarry - DarioHealth Corp President and Chief Commercial Officer

DRIO Stock  USD 0.79  0.07  9.72%   

President

Mr. Olivier Jarry is President and Chief Commercial Officer of the Company. Mr. Jarry has served on the Companys Advisory Board and as a Strategic Advisory consultant since 2017. Between 2015 and 2016, he served as Senior VicePresident of the Consumer Sector and Officer at Intrexon Corporationration, a biotechnology company focused on engineering biological systems to enable DNAbased control over the function and output of living cells. Prior to Intrexon, from 2011 to 2012, Mr. Jarry served as the Head of Strategy, Operations and Market Access, focusing on Emerging Markets, for BristolMyers Squibb, where he oversaw the product launch and growth of innovative medicines relating to oncology, virology, rheumatology, cardiovascular, and diabetes. Prior to that, between 2009 and 2010, Mr. Jarry served as the Global Business Unit Head of Bayer Diabetes Care, a division of Bayer HealthCare Pharmaceuticals LLC. Prior to his time at Bayer HealthCare, from 2001 to 2009, Mr. Jarry served in several leadership roles at Novartis International AG, including working as Global Division Head of Strategy, Business Development Licensing at Novartis Headquarters in Switzerland, Senior Vice President and Region Head for Latin America and for AsiaPacific for Novartis Consumer Health Division, Head of India Rural Business and Head of WesternEastern Europe, Russia, CIS Vaccines division since 2018.
Age 63
Tenure 6 years
Professional MarksMBA
Address 122 W 57th St,, New York, NY, United States, 10019
Phone972 477 0637 7
Webhttps://www.dariohealth.com
Jarry holds a M.Sc. degree from Ecole Centrale de Paris, a MEng. degree from Délégation Générale pour l’Armement, and a Trium Executive MBA degree jointly awarded by NYU Stern School of Business, London School of Economics and Political Science and Hautes Études Commerciales Paris.

DarioHealth Corp Management Efficiency

The company has return on total asset (ROA) of (0.3474) % which means that it has lost $0.3474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7491) %, meaning that it created substantial loss on money invested by shareholders. DarioHealth Corp's management efficiency ratios could be used to measure how well DarioHealth Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -1.26. In addition to that, Return On Capital Employed is likely to drop to -0.7. At this time, DarioHealth Corp's Debt To Assets are very stable compared to the past year. As of the 1st of December 2024, Asset Turnover is likely to grow to 0.36, while Non Currrent Assets Other are likely to drop about 92.5 K.
DarioHealth Corp currently holds 29.54 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. DarioHealth Corp has a current ratio of 6.22, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about DarioHealth Corp's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 14 records

PRESIDENT Age

Patrick SchmitzNevro Corp
64
Aviva McPherronOrthofix Medical
N/A
Jon SerbousekOrthofix Medical
63
Scott YerbySi Bone
56
Daniel GerritzenOrthopediatrics Corp
54
Carlton RecklingSi Bone
62
Kevin KennyOrthofix Medical
59
Kimberley EltingOrthofix Medical
59
Gregory OdleOrthopediatrics Corp
54
Joseph HauserOrthopediatrics Corp
42
Christopher ChristoforouNevro Corp
50
MBAMSHA CHEOrthopediatrics Corp
52
Tyler LipschultzOrthofix Medical
57
David BaileyOrthopediatrics Corp
45
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York. Dario Health operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 200 people. DarioHealth Corp (DRIO) is traded on NASDAQ Exchange in USA. It is located in 122 W 57th St,, New York, NY, United States, 10019 and employs 276 people. DarioHealth Corp is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

DarioHealth Corp Leadership Team

Elected by the shareholders, the DarioHealth Corp's board of directors comprises two types of representatives: DarioHealth Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DarioHealth. The board's role is to monitor DarioHealth Corp's management team and ensure that shareholders' interests are well served. DarioHealth Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DarioHealth Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Tomer BenKiki, Chief Officer
Zvi CPA, Treasurer CFO
Josh Fischer, Senior Compliance
Dov Oppenheim, CoFounder Chief
Brian Harrigan, Senior Sales
Richard Anderson, President
Claudia Levi, Content Manager
Jean Muyl, Head America
Zvi David, Treasurer CFO
Kat Parrella, Investor Manager
Dror Bacher, Chief Officer
Erez Raphael, Chairman, CEO and Pres
Mona Dean, Chief Officer
Mary Mooney, Vice Marketing
Limor Drezner, Chief Officer
Olivier Jarry, President and Chief Commercial Officer
Omar MD, Chief Officer

DarioHealth Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DarioHealth Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with DarioHealth Corp

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DarioHealth Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DarioHealth Corp will appreciate offsetting losses from the drop in the long position's value.

Moving against DarioHealth Stock

  0.73GH Guardant HealthPairCorr
  0.65LH LaboratoryPairCorr
  0.58DXCM DexCom Inc Sell-off TrendPairCorr
  0.52VREX Varex Imaging CorpPairCorr
  0.48VEEV Veeva Systems Class Earnings Call This WeekPairCorr
The ability to find closely correlated positions to DarioHealth Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DarioHealth Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DarioHealth Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DarioHealth Corp to buy it.
The correlation of DarioHealth Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DarioHealth Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DarioHealth Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DarioHealth Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether DarioHealth Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DarioHealth Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dariohealth Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dariohealth Corp Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DarioHealth Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in DarioHealth Stock, please use our How to Invest in DarioHealth Corp guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DarioHealth Corp. If investors know DarioHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DarioHealth Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.93)
Revenue Per Share
0.631
Quarterly Revenue Growth
1.11
Return On Assets
(0.35)
Return On Equity
(0.75)
The market value of DarioHealth Corp is measured differently than its book value, which is the value of DarioHealth that is recorded on the company's balance sheet. Investors also form their own opinion of DarioHealth Corp's value that differs from its market value or its book value, called intrinsic value, which is DarioHealth Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DarioHealth Corp's market value can be influenced by many factors that don't directly affect DarioHealth Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DarioHealth Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if DarioHealth Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DarioHealth Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.